Efficacy And Safety Of Dutasteride In The Treatment Of Alopecia: A Comprehensive Review

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.

This study found that men who smoke are more likely to develop androgenetic alopecia and experience disease progression compared to non-smokers.

This study compared the effectiveness of topical finasteride, oral finasteride, and topical minoxidil over 12 months in postmenopausal women with androgenetic alopecia, exploring their therapeutic effects on this population. Results are not reported in the abstract.

This systematic review concluded that mesotherapy shows potential for improving hair growth outcomes, yet lacks standardized regimens and requires further large-scale trials to establish its efficacy and safe use.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.

This study concluded that combining 5% minoxidil with microneedling was more effective in improving hair density at 6 months for adults with pattern hair loss compared to other treatments analyzed.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

This study observed that a CBD-rich topical cannabis extract may increase hair count in patients with androgenetic alopecia when applied daily, but the effect is concentration-dependent and requires further research to establish safety and efficacy.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.

This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.

Natural products like saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil could potentially treat male hair loss.

This review reports that clinical studies generally showed favorable results for microneedling as an adjunct therapy for androgenic alopecia and alopecia areata, despite the low quality of existing data.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This review examines the potential use and challenges of topical cannabinoids for skin diseases and hair growth, highlighting limited clinical data on their efficacy and safety.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

In this overview, the authors note that both pharmacologic and nonpharmacologic treatments are effective for pattern hair loss, emphasizing early detection and intervention to maintain hair.

This pharmacovigilance study found an increased association of suicidality and psychological adverse events with finasteride use, especially among younger patients using it for alopecia.

This study demonstrates that massage significantly enhances the follicular targeting of dutasteride-loaded nanocapsules, increasing drug accumulation in hair follicles by up to 5 times.

This study found that nanostructured lipid carriers with clobetasol propionate significantly enhance follicular drug delivery compared to commercial cream, and manual massage further doubles follicular retention.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study developed minoxidil sulphate-loaded chitosan nanoparticles that doubled drug delivery to hair follicles in vitro compared to a control solution, suggesting potential for improved alopecia treatment.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study found that both finasteride and dutasteride effectively increased hair thickness in women with androgenetic alopecia over three years, with dutasteride performing better in women under 50 at specific scalp sites.

This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.

This study concluded that mesotherapy with a dutasteride-containing solution was the most effective option for treating androgenetic alopecia in males, promoting hair growth and reducing hair loss.

This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.

This study found that a dutasteride-loaded liposomal system significantly increased skin permeability and drug deposition in mouse skin compared to other formulations, suggesting improved localized treatment potential for androgenetic alopecia.

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

In this case study, significant improvement in androgenic alopecia was observed in a 46-year-old woman after 9 months of treatment with dutasteride following limited success with finasteride.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.